🇺🇸 FDA
Patent

US 12403203

Muscle targeting complexes and uses thereof for treating dystrophinopathies

granted A61KA61K47/6807A61K47/6849

Quick answer

US patent 12403203 (Muscle targeting complexes and uses thereof for treating dystrophinopathies) held by Dyne Therapeutics, Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K47/6807, A61K47/6849, A61K47/6889, A61P